SynthesisNature communications2019
Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk.
Open access · goldAbstract readMeta-Analysis
In one paragraph
Synthesis in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 2 pooled it
11.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Identification of 4 autophagy-related genetic variants as risk factors for chronic lymphocytic leukemia.Blood advances · 2025Pooled it
- Genome-wide trans-ethnic meta-analysis identifies novel susceptibility loci for childhood acute lymphoblastic leukemia.Leukemia · 2022Pooled it
- Cancer-associated fusion transcripts: mechanisms, functional roles, and clinical implications.Clinical and experimental medicine · 2026Review
- Gene-Temperature Interactions and Risk of Childhood Acute Lymphoblastic Leukemia.medRxiv : the preprint server for health sciences · 2026Article
- Characterization of Genetic Etiologic Factors for Pediatric Acute Lymphoblastic Leukemia in Large Childhood Cancer Survivorship Cohorts.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Leukemia risk factor ARID5B coordinates HDAC-mediated transcriptional repression.Nucleic acids research · 2026Article
- A Greek Case-Control Replication Study ofGenes · 2026Article
- RAG-mediated structural variation and its impact on relapse risk in acute lymphoblastic leukemia.medRxiv : the preprint server for health sciences · 2026Article
- Low frequency and rare coding variants affect susceptibility and progression of childhood acute lymphoblastic leukemia.Cancer cell international · 2026Article
- Review
- Targeting β-catenin degradation with GSK3β inhibitors induces cell death in acute lymphoblastic leukemia.Nature cancer · 2026Article
- Genome-wide association study of childhood B-cell acute lymphoblastic leukemia reveals novel African ancestry-specific susceptibility loci.Nature communications · 2025Article
- Familial Patterns in Acute Lymphoblastic Leukemia: Lessons From Three Siblings.Clinical case reports · 2025Article
- Human genetic influences on early B cell development.Journal of human immunity · 2025Review
- Re-envisioning genetic predisposition to childhood and adolescent cancers.Nature reviews. Cancer · 2025Review
- Multi-step gene set analysis identified HTR3 family genes involving childhood acute lymphoblastic leukemia susceptibility.Archives of toxicology · 2025Article
- Expression quantitative trait loci influence DNA damage-induced apoptosis in cancer.BMC genomics · 2024Article
- Concepts in B cell acute lymphoblastic leukemia pathogenesis.Journal of leukocyte biology · 2024Review
- Acute lymphoblastic leukaemia.Nature reviews. Disease primers · 2024Review
- Investigation of inherited noncoding genetic variation impacting the pharmacogenomics of childhood acute lymphoblastic leukemia treatment.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 11 institutions in 5 countries.
Jayaram VijayakrishnanDivision of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.ORCID http://orcid.org/0000-0002-8284-2249
Maoxiang QianDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
James B StuddDivision of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.ORCID http://orcid.org/0000-0002-7157-754X
Wenjian YangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Ben KinnersleyDivision of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.ORCID http://orcid.org/0000-0003-1783-6296
Philip J LawDivision of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.ORCID http://orcid.org/0000-0001-9663-4611
Peter BroderickDivision of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.ORCID http://orcid.org/0000-0002-8348-5829
Elizabeth A RaetzDivision of Pediatric Hematology and Oncology, New York University Langone Health, New York, New York, USA.
James AllanNorthern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.
Ching-Hon PuiDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID http://orcid.org/0000-0003-0303-5658
Ajay VoraGreat Ormond Hospital, London, UK.
William E EvansDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID http://orcid.org/0000-0002-9333-5322
Anthony MoormanWolfson Childhood Cancer Research Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, NE1 7RU, UK.
Allen YeohCentre for Translational Research in Acute Leukaemia, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Wentao YangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Chunliang LiDepartment of Tumor Cell Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID http://orcid.org/0000-0002-5938-5510
Claus R BartramInstitute of Human Genetics, University Hospital, Heidelberg, Germany.
Charles G MullighanDepartment of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.ORCID http://orcid.org/0000-0002-1871-1850
Martin ZimmermanDepartment of Paediatric Haematology and Oncology, Hannover Medical School, 30625, Hannover, Germany.
Stephen P HungerDepartment of Paediatrics and Centre for Childhood Cancer Research, Children's Hospital of Philadelphia and the Perelman School of Medicine at The University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Martin SchrappeDepartment of Paediatrics, University Medical Centre Schleswig-Holstein, Kiel, Germany.
Mary V RellingDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Martin StanullaDepartment of Paediatric Haematology and Oncology, Hannover Medical School, 30625, Hannover, Germany.
Mignon L LohDepartment of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
Richard S HoulstonDivision of Genetics and Epidemiology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. richard.houlston@icr.ac.uk.ORCID http://orcid.org/0000-0002-5268-0242
Jun J YangDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Jun.Yang@stjude.org.ORCID http://orcid.org/0000-0002-0770-9659
St. Jude Children's Research Hospital · USInstitute of Cancer Research · GBMedizinische Hochschule Hannover · DENewcastle University · GBChildren's Hospital of Philadelphia · USGreat Ormond Street Hospital · GBHeidelberg University · DENational University of Singapore · SGNYU Langone Health · USUniversity Hospital Schleswig-Holstein · DEUniversity of California, San Francisco · US
Funding
NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6MCOG FOREIGN ACCRUALU10CA098543 · NCI · NATIONAL CHILDHOOD CANCER FOUNDATION · PI ADAMSON, PETER C. · 2003 to 2013
$335.5MViral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Shondra Michelle Miller · 1985 to 2026
$166.9MCOG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8MChildren's Oncology Group Statistics &Data Center GrantU10CA098413 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI DEVIDAS, MEENAKSHI · 2003 to 2013
$67.5MCPML - Project 3: Genome-wide Studies of Adverse EffectsP50GM115279 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI LOH, MIGNON LEE-CHEUN, RELLING, MARY V · 2015 to 2019
$15.1MSupport for Human Specimen Banking in NCI-Supported Cancer Clinical TrialsU24CA114766 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI RAMIREZ MILAN, NILSA DEL CARMEN · 2005 to 2014
$14.5MPAARK4Kids-Pharmacogenomics of Anticancer Agents Research in ChildrenU01GM092666 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2014
$8.9MNEXT GENERATION SEQUENCING ADD-ON-PHARMACOGENOMICS RESEARCH NETWROK (PGRN)U01GM097119 · NIGMS · WASHINGTON UNIVERSITY · PI MARDIS, ELAINE R · 2010 to 2014
$2.6MARID5B and disparities of childhood leukemiaU01CA176063 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI YANG, JUN J. · 2014 to 2018
$2.4MMedical Research Council MC_PC_19009NCI NIH HHS P30 CA021765NCI NIH HHS U01 CA176063NCI NIH HHS U10 CA098413NCI NIH HHS U10 CA098543NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA114766NIGMS NIH HHS P50 GM115279NIGMS NIH HHS U01 GM092666NIGMS NIH HHS U01 GM097119
Abstract
There is increasing evidence for a strong inherited genetic basis of susceptibility to acute lymphoblastic leukaemia (ALL) in children. To identify new risk variants for B-cell ALL (B-ALL) we conducted a meta-analysis with four GWAS (genome-wide association studies), totalling 5321 cases and 16,666 controls of European descent. We herein describe novel risk loci for B-ALL at 9q21.31 (rs76925697, P = 2.11 × 10
Indexed as
Polymorphism, Single Nucleotidebcl-2 Homologous Antagonist-Killer ProteinChildCore Binding Factor Alpha 2 SubunitEpigenomicsETS Translocation Variant 6 ProteinGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansOncogene Proteins, FusionPrecursor B-Cell Lymphoblastic Leukemia-LymphomaRisk FactorsRNA-Binding ProteinsTranscriptomeBAK1 protein, humanbcl-2 Homologous Antagonist-Killer ProteinCore Binding Factor Alpha 2 SubunitETS Translocation Variant 6 ProteinIGF2BP1 protein, humanOncogene Proteins, FusionRNA-Binding ProteinsTEL-AML1 fusion protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.